Alnylam Pharmace. buy StockNews.com
Start price
15:00
/
50%
€241.90
Target price
21.06.27
-
Performance (%)
-
Price
-
-
Summary
This prediction has just been started. It does not have a price yet.. This prediction currently runs until 21.06.27. The prediction end date can be changed by StockNews_com at any time.Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Alnylam Pharmace. | - |
| iShares Core DAX® | 1.352% |
| iShares Nasdaq 100 | 3.277% |
| iShares Nikkei 225® | 7.434% |
| iShares S&P 500 | 1.702% |
Comments by StockNews_com for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (ALNY) was downgraded by Wall Street Zen from "strong-buy" to "buy".
Ratings data for ALNY provided by MarketBeat